ICER revising assessment of Repatha's cost-effectiveness

In a new evidence update, the Institute for Clinical and Economic Review (ICER) said it intends to lower the value-based price benchmark for PCSK9 inhibitor Repatha evolocumab from Amgen Inc. (NASDAQ:AMGN) based on data from the Phase III FOURIER cardiovascular outcomes trial (CVOT).

Data from FOURIER released in March showed that Repatha significantly reduced risks of myocardial infarction (MI) and stroke, but failed to cut the risk of cardiovascular death. ICER's prior assessment had assumed that the drug would lead to a mortality benefit (see BioCentury Extra, March 17)...